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Background. Conflicting results about the effects of community-based pulmonary 19 
rehabilitation in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) 20 
exist, possibly because the variety of outcome measures used and the lack of appropriate 21 
measurement properties hinder the development of pulmonary rehabilitation guidelines. 22 
Purpose. The purpose of this study was to identify and review the measurement properties of 23 
patient-reported outcome measures (PROMs) and clinical outcome measures of AECOPD that 24 
are used in pulmonary rehabilitation and that can be easily applied in a community setting. 25 
Data Sources. PubMed, Web of Science, Scopus, and CINAHL were searched up to July 1, 26 
2016. 27 
Study Selection. Phase 1 identified outcome measures used in pulmonary rehabilitation for 28 
AECOPD. Phase 2 reviewed the measurement properties of the identified outcome measures. 29 
Data Extraction. One reviewer extracted the data and 2 reviewers independently assessed the 30 
methodological quality of the studies and the measurement properties of the outcome 31 
measures by using the Consensus-Based Standards for the Selection of Health Status 32 
Measurement Instruments (COSMIN) recommendations. 33 
Data Synthesis. Twenty-three PROMs and 18 clinical outcome measures were found. The 34 
outcome measures most used were the St George Respiratory Questionnaire (n = 15/37 35 
studies) and the 6-minute walk test (n = 21/37 studies). Thirty-two studies described the 36 
measurement properties of 22 PROMs and 7 clinical outcome measures. The methodological 37 
quality of the studies was mostly poor, and the measurement properties were mostly 38 
indeterminate. The outcome measure exhibiting more robust properties was the COPD 39 
Assessment Test. 40 
Limitations. A number of studies were published without the validated search strategy used 41 
and were included a posteriori; the fact that 3 studies presented combined results for patients 42 
who were stable and patients with exacerbation, affected the conclusions that can be drawn. 43 
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Conclusions. A large variety of outcome measures have been used; however, studies on their 44 
measurement properties are needed to enhance the understanding of community pulmonary 45 
rehabilitation for AECOPD. 46 
  47 
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Chronic obstructive pulmonary disease (COPD) is frequently punctuated by acute 48 
exacerbations (AECOPD).1 Currently, more than 80% of these events are recommended to be 49 
managed within the community since it can shorten the length of hospital stays and/or avoid 50 
hospital admittance.2 51 
 52 
Pulmonary rehabilitation is a well-established, evidenced-based intervention, possible to be 53 
applied within the community (ie, in nonspecialized community health services, in 54 
community centers, or at the patient’s home)3–6 and with potential to prevent and decrease the 55 
harmful effects of acute exacerbations.7 Costs associated with AECOPD in the United States 56 
are estimated in $7100 per patient/per exacerbation8 and recent economic studies have shown 57 
that, compared with usual care, community-based pulmonary rehabilitation provides cost 58 
savings of $1098 per patient.9 59 
 60 
Nevertheless, conflicting results regarding the clinical effects of pulmonary rehabilitation in 61 
AECOPD have been reported10,11 and less than 10% of patients discharged from AECOPD are 62 
being referred for pulmonary rehabilitation12 thus, its implementation is not a common 63 
practice. This inconsistency among studies may occur due to the wide variety of outcomes 64 
and outcome measures used and/or due to the lack of appropriate measurement properties (ie, 65 
reliability, validity and responsiveness) of the outcome measures used in exacerbation 66 
periods. It is known that the measurement properties of any outcome measure are population 67 
specific13 and that patients at distinct phases of their chronic disease (stable/exacerbation) 68 
differ in the physiologic and ventilatory mechanisms of their lungs.14 Therefore, it can be 69 
hypothesized that instrument measurement properties will also vary in stable and exacerbation 70 
periods. 71 
 72 
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Nevertheless, studies involving pulmonary rehabilitation in patients with AECOPD have been 73 
choosing their outcome measures based on the measurement properties established for stable 74 
patients with COPD,15,16 which may hinder the development of pulmonary rehabilitation 75 
guidelines and lead instead to publication of recommendations which lack rigorous 76 
underpinning evidence in exacerbation periods. 77 
 78 
Additionally, attending to patient’s level of fragility during exacerbations, the specificities of 79 
implementing a pulmonary rehabilitation program in a nonspecialized center and some 80 
practical issues, such as the need for specific equipment and sufficient space and time required 81 
to complete testing, especially when more than 1 test at baseline is required, may also 82 
influence the selection of the outcome measure.17 83 
 84 
Thus, the 2 aims of this systematic review were to identify patient-reported outcome measures 85 
(PROMs) and clinical (non–patient-reported) outcome measures that are used to assess the 86 
effects of pulmonary rehabilitation interventions in patients with AECOPD and that can be 87 
easily applied in the community (ie, not expensive, not invasive, and quickly implemented) 88 
and to synthesize/evaluate their measurement properties. 89 
 90 
Methods 91 
This systematic review (PROSPERO registration no. CRD42015023736) was conducted in 2 92 
phases. Phase 1 identified outcome measures used to assess outcomes of pulmonary 93 
rehabilitation interventions in patients with AECOPD and that can be easily applied in 94 
community-based practice. Phase 2 aimed to assess the measurement properties of the 95 
identified outcome measures. 96 
Phase 1: Measures Used in Pulmonary Rehabilitation 97 
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Data sources and searches. The effects of pulmonary rehabilitation interventions in patients 98 
with AECOPD have been largely reviewed,10,11,18–21 thus a first search limited to literature 99 
reviews was conducted from May to June 2016 in PubMed, Web of Knowledge, Scopus, and 100 
CINAHL. The original papers included in these reviews were extracted and searched for the 101 
outcome measures. 102 
 103 
The latest available literature review on this theme was dated from 2012 and thus, a second 104 
search using the same keywords and databases but limited to original studies published from 105 
2010 to June 2016 was also performed to identify all outcome measures most recently used by 106 
physiotherapists. An interval of 2 years until the most recent review in the theme seemed 107 
appropriate, as studies indicate that time from submission to publication can go up to 2 108 
years.22 In both searches, the reference lists of the identified studies were scanned for other 109 
potential eligible studies. Additionally, a weekly update was conducted until July 2016. The 110 
full search strategy can be found in eAppendix 1 (available at: https://academic.oup.com/ptj). 111 
Study selection. Selection of studies was performed by 1 reviewer (A.L.O.) and checked by a 112 
second reviewer (A.S.M.). After removing duplicates, 1 reviewer (A.L.O.) performed the 113 
initial screening of articles based on type of publication and relevance for the scope of the 114 
review. Selection of studies checked by a second reviewer (A.S.M.). 115 
 116 
First, title and abstract were screened, and if the articles were considered relevant, full text 117 
was analyzed. Studies were included if they met the following 3 criteria: aimed to assess 118 
pulmonary rehabilitation or one of its components; assessed patients with an AECOPD within 119 
3 weeks of the onset as this is the mean time needed for recovery2,23,24; and were written in 120 
English, Spanish, French, or Portuguese. Studies were excluded if they were conducted in 121 
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animals; patients requiring emergency intubation, intensive care unit management, and/or 122 
mechanical ventilation; patients with compromised neurological status or hemodynamic 123 
instability; patients performing self-management programs only; and patients assessed only 124 
after discharge for AECOPD. Book chapters, abstracts of communications or meetings, letters 125 
to the editor, commentaries to studies, unpublished work and study protocols were excluded. 126 
 127 
Data extraction. Data extraction focused on PROMs and clinical outcome measures used to 128 
assess pulmonary rehabilitation interventions and that can be easily applied in community-129 
based practice. Thus, data regarding measures not suitable for this setting (eg, arterial blood 130 
gases, cardiopulmonary exercise testing, body plethysmography studies, sputum weight and 131 
analysis; penetration index of inhaled radioparticles and hospital length of stay) were not 132 
extracted. Data extracted were: outcomes, outcome measures, patient characteristics (ie, age 133 
and percentage of predicted forced expiratory volume in 1 second (FEV1) at stability or in 134 
acute exacerbation), treatment setting, time from AECOPD to intervention and duration of 135 
intervention. 136 
 137 
Phase 2: Properties of Measures 138 
Data sources and searches. A systematic electronic literature search was conducted from 139 
June to July 2016 on PubMed, Web of Science, Scopus, and CINAHL. A validated sensitive 140 
search filter (sensitivity = 97.4%; precision = 4.4%) for finding studies on measurement 141 
properties of outcome measures was used.25 Only outcome measures included in phase 1 were 142 
searched in phase 2, however, if new outcome measures feasible to be used in community 143 
practice emerged from the search, they were also included. Reference lists of the identified 144 
 8 
 
studies were scanned for other potential eligible studies and a weekly update was conducted 145 
until September 2016. The full search strategy can be found in eAppendix 2 (available at: 146 
https://academic.oup.com/ptj). 147 
 148 
Study selection. Selection of studies was performed by 1 reviewer (A.L.O.) and checked by a 149 
second reviewer (A.S.M.). Inclusion and exclusion criteria were as in phase 1. Additionally, 150 
studies were included if information was reported regarding 1 or more measurement 151 
properties (ie, reliability – internal consistency, reliability, measurement error; validity – 152 
content validity, construct validity and criterion validity, responsiveness and interpretability). 153 
Studies were excluded if reported on measurement properties of outcome measures not 154 
feasible to use in community-based pulmonary rehabilitation programs, separated items of an 155 
outcome measure and did not included the full measure. 156 
 157 
Data extraction and quality assessment. Data was extracted by 1 reviewer (A.L.O.) using 2 158 
standardized tables, one for PROMs and another for clinical outcome measures. Data 159 
extracted were: outcome, outcome measure, author and year of publication, measurement 160 
property assessed, quality of the study, quality of the measurement property and costs. 161 
 162 
Two independent reviewers (A.L.O. and A.S.M.) evaluated the quality of the included studies 163 
using the Consensus-Based Standards for the Selection of Health Status Measurement 164 
Instruments (COSMIN) checklist (ie, poor, fair, good, excellent).26 A consensus method was 165 
used to solve disagreements between reviewers. 166 
 167 
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The quality of the outcome measures reported was determined using the rating system for 168 
measurement properties proposed by Terwee et al.27 For each measurement property a 169 
criterion is defined for positive, negative and indeterminate rating. 170 
 171 
Data synthesis and analysis. Data on PROMs and clinical outcome measures were separately 172 
analyzed. For each measurement property (ie, reliability, validity, responsiveness and 173 
interpretability), a synthesis of the quality of the study, using the COSMIN criteria,26 and of 174 
the quality outcome measure, using the system of Terwee et al,27 was performed. 175 
 176 
The consistency of the quality assessment performed by the 2 reviewers was explored with an 177 
interrater agreement analysis using the Cohen kappa for each box of the COSMIN criteria. 178 
The Cohen kappa value ranges from 0 to 1 and can be categorized as slight (< 0.2), fair (0.21–179 
0.4), moderate (0.41–0.6), substantial (0.61–0.8), or almost perfect (> 0.81) agreement.28 180 
 181 
Results 182 
Phase 1: Measures Used in Pulmonary Rehabilitation 183 
Study selection. A total of 220 literature reviews were found. After duplicates were removed 184 
(n = 66) and exclusions were made on the basis of abstract and title screenings (n = 22), 132 185 
full texts were screened and 15 literature reviews that reported on pulmonary rehabilitation 186 
interventions in patients with AECOPD were included. Additionally, 24 original studies 187 
included in the 15 reviews were extracted and searched for outcome measures not reported in 188 
the reviews. 189 
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 190 
The search conducted for original studies published after 2010 retrieved 257 original studies. 191 
After duplicates were removed (n = 134) and exclusions were made on the basis of abstract 192 
and title screenings (n = 23), 100 full texts were screened and 13 original studies were 193 
included. Thus, a total of 37 original studies were searched for outcome measures. A flow 194 
diagram concerning the literature reviews and original studies search and reasons for studies 195 
exclusions can be found in the Figure. 196 
 197 
Study characteristics. The 37 studies included were conducted in 19 different countries. A 198 
steady increase in the number of studies investigating pulmonary rehabilitation in patients 199 
with AECOPD was observed, with only 7 papers published from 1964 to 2000 and 37 by 200 
2016. Most studies were randomized control trials (n = 31)15,16,29–57 conducted with inpatients 201 
(n = 27),15,16,29,30,33,35,37–41,43,45–48,51–61 followed by hospital outpatient departments (n = 202 
6),15,37,38,42,44,49 inpatients plus patients’ homes (n = 3),31,32,50 community settings (n = 3),34,62,63 203 
and patients’ homes (n = 1)36 (Tabs. 1 and 2). 204 
Outcomes and outcome measures. Twenty-three PROMs and 18 clinical outcome measures 205 
were identified. The most common patient-reported outcomes assessed were dyspnea (n = 24), 206 
using the modified Borg Scale (mBorg)30,32,38,39,42,44,46,52–55,58,62,63 (n = 14), and health-related 207 
quality of life (n = 23), using the St George Respiratory Questionnaire (SGRQ)16,34-37,39,42,44,49–208 
51,54,56,58,59 (n = 15). The most common clinical outcomes assessed were functional exercise 209 
capacity (n = 24), using the 6-minute walk test16,30-32,37,38,41,43,44,48,49,51–53,56,58,63 (n = 21), and 210 
lung function (n = 13), using the FEV1
16,30,31,36,39,44,55,57,60,61 (n = 10). Other outcomes assessed 211 
were anxiety and depression, fatigue, cough, physical activity, strength, activities of daily 212 
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living, lung function, peripheral blood gases, subjective airway clearance, and body 213 
composition. 214 
 215 
Tables 1 and 2 show the patient-reported and clinical outcomes and outcome measures 216 
reported. 217 
 218 
Phase 2: Properties of Measures 219 
Study selection. The search for measurement properties identified 82 studies. After the 220 
removal of duplicates, 41 studies were screened. During the title and abstract screening, 18 221 
studies were excluded. The full text of 23 studies was assessed and another 15 studies were 222 
excluded. Therefore, 8 original studies were selected. The search for relevant studies within 223 
the reference lists retrieved 24 additional studies. Therefore, a total of 32 studies were 224 
included in this review (Figure). 225 
 226 
Measurement properties. The measurement properties of 22 PROMs used to assess 5 227 
outcomes (ie, dyspnea [6 outcome measures], health-related quality of life [11 outcome 228 
measures], health status [2 outcome measures], activities of daily living [2 outcome 229 
measures], and general symptoms [1 outcome measure]) were reported by 26 of 32 studies. 230 
The measurement properties of 7 clinical outcome measures used to assess 4 outcomes (ie, 231 
oxygen saturation [1 outcome measure], lung function [4 outcome measures], body 232 
composition [1 outcome measure], and physical activity [1 outcome measure]) were reported 233 
in 8 of 32 studies. 234 
 235 
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The methodological quality of each study and the quality of the measurement properties of 236 
each measure can be found in Tables 3 and 4. The agreement between the 2 independent 237 
reviewers using the COSMIN quality assessment was substantial (κ = 0.688). 238 
 239 
The characteristics of the included studies and synthesis of the results per outcome and 240 
outcome measure can be found in eAppendix 3 (available at: https://academic.oup.com/ptj; 241 
eTab. 1a and eTab. 1b). 242 
 243 
Quality and properties of PROMs. Reliability was studied for 5 PROMs in 5 studies of fair 244 
to excellent methodological quality (ie, SGRQ, Chronic Respiratory Diseases Questionnaire 245 
[CRQ], Clinical COPD Questionnaire [CCQ], and COPD Assessment Test [CAT])64–68 and in 246 
2 studies of poor methodological quality (ie, CCQ and Exacerbations of Chronic Pulmonary 247 
Disease Tool–Patient-Reported Outcome [EXACT-PRO]).67,69 Studies were rated as poor 248 
mainly because an analysis of the unidimensionality of the scale was not preformed. 249 
 250 
Measurement properties presented positive results in all reliability categories assessed (ie, 251 
internal consistency and test-retest; measurement error has not been assessed) and for all 252 
outcome measures (Tab. 3). 253 
 254 
Validity was studied for most PROMs, except for the mBorg, visual analog scale, Short-Form 255 
6D, and Nottingham Health Profile, in 21 studies.64–84 Overall, the methodological quality of 256 
the studies was rated from poor to fair, except for structural validity studied in the CRQ and 257 
the CAT, which were rated excellent.64,65 For criterion validity, reasons for rating “poor” were 258 
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related with the inadequacy of the gold standard used as comparator. Regarding to construct 259 
validity, weaknesses included lack of formulation of hypotheses and lack of description of the 260 
comparator instrument. 261 
 262 
Criterion validity was indeterminate in 5 studies (ie, modified Medical Research Council 263 
[MRC], MRC, extended MRC, CCQ, COPD severity score, EuroQol 5D [EQ-5D], Breathing 264 
Problems Questionnaire, London Chest Activities of Daily Living Scale [LCADL], and 265 
Manchester Respiratory Activities of Daily Living Questionnaire)70,71,77,79,81 and positive in 1 266 
study (ie, Global Initiative for Chronic Obstructive Lung Disease plus Symptom Severity 267 
Index [GOLD + SSI]).83 Structural validity presented positive results in 2 studies (ie, CRQ 268 
and CAT).64,65 Construct validity, was indeterminate in 11 studies (ie, Baseline Dyspnea 269 
Index and Transition Dyspnea Index [BDI/TDI], SGRQ, CRQ, CCQ, COPD severity score, 270 
EQ-5D, Short-Form 6D, Measure Your Medical Outcome Profile, and Medical Outcomes 271 
Study 6-Item General Health Survey, modified MRC, SGRQ, EXACT-PRO, and 272 
LCADL)66,68-70,72,75,76,79,80,82, negative in 2 studies (ie, SGRQ and CRQ)64,73, and positive in 7 273 
studies (ie, SGRQ, CRQ, CCQ, CAT, and Cough and Sputum Assessment 274 
Questionnaire)65,67,74-76,78,84 (Tab. 3). 275 
 276 
Responsiveness was studied for most PROMs, except for the modified MRC, MRC, extended 277 
MRC, Breathing Problems Questionnaire, GOLD + SSI, Manchester Respiratory Activities of 278 
Daily Living Questionnaire, and LCADL, in 19 studies of poor to fair methodological 279 
quality.64,66–69,72–77,79,80,84–89 Common weaknesses of studies included lack of description of the 280 
comparator instrument and inadequacy of design and statistical methods used. 281 
 282 
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Responsiveness was indeterminate in 14 studies (ie, SGRQ, CCQ, COPD severity score, EQ-283 
5D, Short-Form 6D, Nottingham Health Profile, Measure Your Medical Outcome Profile, 284 
Medical Outcomes Study 6-Item General Health Survey, EXACT-PRO, Cough and Sputum 285 
Assessment Questionnaire, mBorg, visual analog scale, and CCQ),66–69,73,75,77,79,80,84–87,89 286 
negative in 5 studies (ie, SGRQ, CRQ, CAT, and EQ-5D),64,72,74,75,79 and positive in 3 studies 287 
(ie, BDI/TDI and CAT)72,76,88 (Tab. 3). 288 
 289 
Interpretability was found in 2 studies which presented values of the minimal clinically 290 
important difference (MCID) for the CRQ (MCID = 1.01)64 and the CCQ (MCID = 0.44).68 291 
 292 
Quality and properties of clinical measures. Reliability was not studied for any of the 293 
clinical outcome measures found (Tab. 4). 294 
 295 
Validity was studied for all clinical outcome measures in 8 studies of fair to poor 296 
methodological quality.70,72,90–95 For criterion validity, reasons for rating “poor” were related 297 
with the inadequacy of the gold standard used as comparator, whereas for construct validity 298 
reasons were related to the lack of formulation of hypotheses and the lack of description of the 299 
comparator instrument. 300 
 301 
Overall, measurement properties presented positive results for criterion validity assessed in 4 302 
studies (ie, peripheral oxygen saturation [SpO2], forced vital capacity, and computerized 303 
respiratory sounds)70,90,93,94; however, in 1 study assessing the FEV1, criterion validity was 304 
indeterminate.70 Regarding to construct validity, indeterminate results were found in 2 studies 305 
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(ie, SpO2, peak expiratory flow [PEF], FEV1, and forced vital capacity)
70,92 and positive 306 
results in 3 studies (ie, SpO2, PEF, and time spent in weight-bearing activities assessed with 307 
an accelerometer)90,91,95 (Tab. 4). 308 
 309 
Responsiveness was studied for the PEF and FEV1 in 2 studies
72,91 of fair and poor 310 
methodological quality, respectively. The study was rated as poor because it did not describe 311 
the measurement properties of the comparator instrument. 312 
 313 
Responsiveness was rated positive for the PEF91 and indeterminate for the FEV1
72 (Tab. 4). 314 
 315 
Interpretability was not studied for any of the clinical outcome measures found (Tab. 4). 316 
 317 
Discussion 318 
To our knowledge, this is the first systematic review to provide a comprehensive overview of 319 
the measurement properties of the outcome measures most used in pulmonary rehabilitation 320 
programs during AECOPD and that can be easily applied in a community setting. Twenty-321 
three PROMs and 18 clinical outcome measures were identified in intervention studies. The 322 
most used measures were the St George Respiratory Questionnaire (n = 15/37) and the 6-323 
minute walk test (n = 21/37). Several measures have been used only in isolated studies (ie, 324 
New York Heart Association Functional Classification, Activities of Daily Living Dyspnea 325 
Scale, diaries, Functional Assessment of Chronic Illness Therapy, feeling thermometer, 326 
mBorg fatigue, LCADL, 3-minute step test, 3-minute walk test, 2-minute step-in-place test, 327 
FEV1/forced vital capacity, computerized respiratory sounds, fat-free mass index, body mass 328 
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index, accelerometer, quadriceps twitch responses, and maximum inspiratory pressure). 329 
Measurement properties were only synthesized for 22 PROMs and 7 clinical outcome 330 
measures. The methodological quality of most studies was poor, and the results obtained for 331 
the measurement properties were indeterminate. The PROMs and clinical outcome measures 332 
exhibiting the most appropriate measurement properties were the CAT and SpO2, 333 
respectively. 334 
 335 
The most used PROMs were the mBorg and the SGRQ. Dyspnea and health-related quality of 336 
life have been reported as the outcomes that better reflect the overall impact of the disease96 337 
and, therefore their monitoring during AECOPD, with appropriate outcome measures, is 338 
essential to guide health professionals on the most effective interventions. Nevertheless, the 339 
measurement properties of the mBorg have been little reported and, when reported, in studies 340 
of poor methodological quality. The BDI/TDI, although not commonly used, was the only 341 
outcome measure which rated fair and positive for responsiveness on dyspnea. The SGRQ has 342 
shown appropriate test retest reliability but inconclusive validity and responsiveness. 343 
Although, the SGRQ has strong measurement properties in stable patients with COPD,24,97 it 344 
reports to the past month, 3 months and 1 year. These inappropriate timeframes to assess 345 
improvements from an AECOPD, which usually takes 1 to 3 weeks to be meaningful to 346 
patients,23,98 might explain some of the divergent results found. Measurement properties of 347 
CAT have been assessed in a reasonable number of studies of fair methodological 348 
quality65,75,76,78,88 and positive results have been found. Therefore, the BDI/TDI and CAT may 349 
be promising PROMs to assess the effectiveness of community-based pulmonary 350 
rehabilitation in patients with AECOPD. 351 
 352 
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The most used clinical outcome measures were the FEV1 and the 6-minute walk test. 353 
However, the measurement properties of the FEV1 were found in studies of poor 354 
methodological quality and no studies were found reporting on the measurement properties of 355 
the 6-minute walk test in patients with AECOPD which impaired conclusions regarding its 356 
use. Similarly to exercise tolerance, no studies were found reporting on measurement 357 
properties of muscle strength. Currently, it is known that the inflammatory effects of 358 
AECOPD are not confined to the lungs but also impair peripheral muscle strength and 359 
exercise tolerance.1 Declines in these outcomes are independent predictors of hospitalizations 360 
and mortality.99,100 Early rehabilitation may play a crucial role in preventing and reducing 361 
losses in exercise capacity, muscle strength and musculoskeletal dysfunction,16,43 thus 362 
possibly reverting this cascade of events. Nevertheless, there is the urgent need to establish 363 
the measurement properties of clinical outcome measures for AECOPD to assess patients’ 364 
dysfunctions, plan interventions, and verify their effectiveness. 365 
 366 
This systematic review evidenced that the conflicting results of pulmonary rehabilitation 367 
programs in patients with AECOPD10,15,16,50 may not be related to the quality of treatment but 368 
with the lack of appropriateness of measurement proprieties of the outcome measures used. 369 
Additionally, whilst the methodology of this review target only measures that could be 370 
implemented in community settings (ie, simple and accessible measures), our results can also 371 
be applicable to other clinical settings where these measures are available. Nevertheless, since 372 
most AECOPD are recommended to be managed in the community and community-based 373 
pulmonary rehabilitation might be a promising intervention for minimizing a patient’s decline 374 
and prevent recurrence, robust studies on the validity, reliability and responsiveness, as well 375 
as on availability, cost and interpretability (ie, by establishing the MCID), of outcome 376 
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measures are urgently needed. These studies will contribute to clarify the role of community-377 
based pulmonary rehabilitation in patients with AECOPD. 378 
 379 
Study Limitations 380 
This study has some limitations that need to be acknowledged. Several relevant studies for 381 
this systematic review67–69,71–73,75,77–79,81–83,85,86,88–95 were not found with the validated search 382 
strategy used and were only included after searching through the reference lists of the 383 
reviewed studies. Relevant studies may have fallen out of the search due the absence of 384 
keywords related to measurement properties in their title, abstract or keywords, which 385 
impaired the filter used to identify them. Adequate use of the Medical Subject Headings 386 
(MESH) terms is warranted to identify the purpose of the studies and improve the quality of 387 
the results found in future systematic reviews. 388 
 389 
This systematic review has followed the COSMIN recommendations to assess the quality of 390 
the included studies. The COSMIN was originally developed for health-related PROMs, such 391 
as questionnaires,26 and thus its validity, reliability and adequacy for assessing the 392 
methodological quality of clinical studies and outcome measures, may be questioned. 393 
Nonetheless, in the absence of a measure specifically designed to evaluate such studies and 394 
outcome measures, the COSMIN is indicated as an adequate alternative tool.101,102 395 
 396 
The selection of studies was performed by 1 reviewer which could have caused bias in the 397 
studies selection. This limitation has been mitigated by consulting a second reviewer when 398 
uncertainties were found and by defining strict inclusion and exclusion criteria prior to studies 399 
selection. 400 
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 401 
Finally, 3 of the studies included presented combined results of stable and exacerbated 402 
patients with COPD69,73,74 which could have affected some of the conclusions established. 403 
Nevertheless, the results of these studies have been considered within the universe of all 404 
studies included, and thus we believe that any potential bias that could have been introduced 405 
was diluted. Future studies should focus on patients with AECOPD only, so that 406 
recommendations regarding its measurement properties can be established with confidence. 407 
 408 
Conclusions 409 
Although a large number of outcome measures easy to implement in a community-based 410 
setting have been used to assess pulmonary rehabilitation in patients with AECOPD, their 411 
measurement properties have been poorly studied. Given the wide availability of measures it 412 
does not seem necessary to develop new outcome measures to be used in community-based 413 
pulmonary rehabilitation of patients with AECOPD. Instead, studies following the COSMIN 414 
standards to evaluate the measurement properties (ie, reliability, validity and responsiveness) 415 
of the existing outcome measures are recommended. Such studies would contribute to clarify 416 
the role of community-based pulmonary rehabilitation in patients with AECOPD and guide 417 
the development of core outcome sets. 418 
  419 
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Table 1. 739 
Patient-Reported Outcomes Used in Pulmonary Rehabilitation of Patients With Acute Exacerbation (AE) of Chronic Obstructive Pulmonary 740 
Disease (COPD)a 741 
Outcome Outcome Measure Patient Characteristics Intervention 
Setting 
Intervention 
Timing 
Intervention 
Duration 
No. of 
Patients 
Age 
(y) 
FEV1pp 
(%) 
FEV1ppAE 
(%) 
FEV1ppST 
(%) 
Dyspnea BDI/TDI30–32 26–30 62.3–
69 
 34.1–60  Inpatient and 
home 
4–8 d after 
hospital 
presentation 
11 d–18 mo 
VAS35,60 1–27 68.4–
74 
NS   Inpatient At hospital 
presentation 
to 2 d after 
hospital 
presentation 
45 min–2 
mo 
Borg Scale33,36,41 26–110 61–75   35–42 Inpatient and 
home 
At hospital 
presentation 
to hospital 
discharge 
Until 
hospital 
discharge to 
6 wk 
mBorg30,32,38,39,42,44,46,52–
55,58,62,63 
19–
1,826 
45–
78.8 
 34.1–69.4 50.5–56 Inpatient, 
hospital 
outpatient 
department, 
and 
At hospital 
presentation 
to 3 wk after 
discharge 
60 min–19 
mo 
 29 
 
community 
MRC36,39,49,52,59 19–94 58.4–
73.9 
 38–53.3 29–56 Inpatient, 
hospital 
outpatient 
department, 
and home 
At hospital 
presentation 
to 2 wk after 
discharge 
Until 
hospital 
discharge to 
12 wk 
mMRC15,38,44,48,51,63 19–97 56.8–
73.8 
(mean) 
 35–69.4 37.3–44.4 Inpatient, 
hospital 
outpatient 
department, 
and 
community 
At hospital 
presentation 
to 3 wk after 
discharge 
Until 
hospital 
discharge to 
12 wk 
NYHA41 38 61 NS   Inpatient As soon as 
stable 
Until 
hospital 
discharge 
ADLDS52 94 69.2–
73.9 
 38–39  Inpatient 2 d after 
hospital 
presentation 
Until 
hospital 
discharge 
HRQL Diary32 26 64–69  34.9–37.5  Inpatient and 
home 
4–7 d after 
admission 
19 mo 
CRQ15,31,32,34,37,38,42,52 19–97 64–
73.9 
 34.1–52 36.7–42.7 Inpatient, 
hospital 
outpatient 
department, 
community, 
and home 
As soon as 
stable to 3.7 
wk after 
hospital 
presentation 
Until 
hospital 
discharge to 
18 mo 
 30 
 
SGRQ16,34–37,39,42,44,49–
51,54,56,58,59 
19–
1,826 
58.4–
78.8 
 35.6–56.1 29–56 Inpatient, 
hospital 
outpatient 
department, 
community, 
and home 
As soon as 
stable to 2 
wk after 
hospital 
presentation 
Until 
hospital 
discharge to 
12 wk 
SF-3634,38,44 24–97 69.6–
73.8 
 35–56.1 36.7–41.7 Inpatient, 
hospital 
outpatient 
department, 
and 
community 
After 
discharge to 
3 wk after 
hospital 
presentation 
8 wk 
EQ-5D36,42,55,56 16–526 65–
73.7 
 52 38–42 Inpatient, 
hospital 
outpatient 
department, 
and home 
As soon as 
stable to 1 
wk after 
hospital 
discharge 
Until 
hospital 
discharge to 
8 wk 
CAT52,61 11–94 69.2–
78 
 34–39  Inpatient 1–2 days 
after hospital 
presentation 
2 d to until 
hospital 
discharge 
FACIT fatigue59 19 71   29 Inpatient Immediately 
at hospital 
presentation 
6 wk 
Feeling thermometer15 19 67.5   42.7 Inpatient or 
hospital 
outpatient 
department 
2 wk after 
hospital 
presentation 
12 wk 
 31 
 
Anxiety 
and 
depression 
HADS38,55 49–97 69.7–
73.7 
35–41   Inpatient and 
hospital 
outpatient 
department 
As soon as 
stable to 
immediately 
after 
discharge 
Until 
hospital 
discharge to 
8 wk 
Fatigue mBorg42 60 65–67 52   Hospital 
outpatient 
department 
1 wk after 
discharge 
8 wk 
Sputum VAS sputum53,61 11–61 68–78  34–39  Inpatient As soon as 
stable 
2–4 d 
General 
symptoms 
BCSS51,56,61,62 11–90 56.8–
78 
 34–69.4 37.3–44.4 Inpatient and 
community 
At hospital 
presentation 
to 72 h after 
hospital 
presentation 
60 min to 
until hospital 
discharge 
ADL Barthel Index33,57 21–110 68–75  45.1–46.1 35–38 Inpatient At hospital 
presentation 
to 72 h after 
hospital 
presentation 
Until 
hospital 
discharge 
LCADL54 44 77.4–
78.8 
 41.8–41.4  Inpatient As soon as 
stable 
8–9 d 
Composite 
measure 
BODE Index38,48,51,52 50–97 65.1–
73.9 
 35–39 37.3–44.4 Inpatient and 
hospital 
outpatient 
department 
At hospital 
presentation 
to 2 d after 
hospital 
presentation 
Until 
hospital 
discharge to 
8 wk 
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aADL = activities of daily living; ADLDS = Activity of Daily Living Dyspnea Scale; AE = acute exacerbation; BCSS = Breathlessness, Cough, 742 
and Sputum Scale; BDI/TDI = Baseline Dyspnea Index and Transition Dyspnea Index; BODE = body mass index, airflow obstruction, dyspnea, 743 
and exercise capacity; CAT = COPD Assessment Test; CRQ = Chronic Respiratory Disease Questionnaire; EQ-5D = EuroQol 5D; FACIT = 744 
Functional Assessment of Chronic Illness Therapy; FEV1pp = percentage predicted forced expiratory volume in 1 s; HADS = Hospital Anxiety 745 
and Depression Scale; HRQL = Health-Related Quality of Life; LCADL = London Chest Activities of Daily Living Scale; mBorg = modified 746 
Borg Scale; MRC = Medical Research Council; mMRC = modified MRC; NS = not stated; NYHA = New York Heart Association Functional 747 
Classification; SF-36 = Short Form (36-Item) Health Survey; SGRQ = St George Respiratory Questionnaire; ST = stable; VAS = visual analog 748 
scale. 749 
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Table 2. 751 
Clinical Outcomes Used in Pulmonary Rehabilitation of Patients With Acute Exacerbation (AE) of Chronic Obstructive Pulmonary Disease 752 
(COPD)a 753 
 754 
Outcome Outcome Measure Patient Characteristics Interventio
n Setting 
Interventio
n Timing 
Interventio
n Duration 
No. of 
Patient
s 
Age 
(y) 
FEV1p
p 
FEV1ppA
E 
FEV1ppS
T 
Functional 
exercise 
capacity 
6MWT16,30–
32,37,38,41,43,44,48,49,51–
53,56,58,63 
28–
1,826 
61–
73.9 
 34.1–69.4 50.5 Inpatient, 
hospital 
outpatient 
department, 
community, 
and home 
At hospital 
presentation 
to 3 wk after 
discharge 
4 d–18 mo 
ISWT34,36,42,50 26–196 65–
71.1 
 52 36.7–51.9 Inpatient, 
hospital 
outpatient 
department, 
community, 
and home 
Immediately 
to 10 d after 
discharge 
6–8 wk 
ESWT42,47,50 20–196 65–
70.1 
 52 39.8–51.9 Inpatient, 
hospital 
outpatient 
department, 
and home 
At hospital 
presentation 
to 1 wk after 
discharge 
Until 
hospital 
discharge to 
8 wk 
 34 
 
3-min step test36 26 65–
67 
  38–42 Home Immediately 
after 
discharge 
6 wk 
3-min walk test57 21 68–
73.6 
 45.1–46.1  Inpatient 48 h after 
hospital 
presentation 
Until 
hospital 
discharge 
2-minute step-in-place 
test55 
49 72.4
–
73.7 
 39–41  Inpatient As soon as 
stable 
Until 
hospital 
discharge 
Oxygen 
saturation 
SpO2
30,38–40,52,55,56,60,62 1–526 56.8
–
73.9 
 35–69.4 52–56 Inpatient, 
hospital 
outpatient 
department, 
and 
community 
At hospital 
presentation 
to 8 d after 
hospital 
presentation 
45 min–8 wk 
Lung 
function 
FEV1
16,30,31,36,39,44,55,57,60,61 1–60 62.3
–78 
 34–56.1 38–56 Inpatient, 
hospital 
outpatient 
department, 
and home 
At hospital 
presentation 
to 3 wk after 
hospital 
discharge 
45 min–18 
mo 
FVC30,31,36,39,61 11–59 62.3
–78 
 34–39 38–56 Inpatient and 
home 
At hospital 
presentation 
to 
immediately 
after hospital 
discharge 
2 d–18 mo 
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FEV1/FVC
39 59 70.2   57.9–64.4 Inpatient At hospital 
presentation 
7 d 
PEF40,41 38–45 61 NS   Inpatient At hospital 
presentation 
Until 
hospital 
discharge 
CRS62 19 56.8  69.4  Community Within 48 to 
72 h after 
hospital 
presentation 
3 wk 
Body 
compositio
n 
Fat-free mass index42 60 65–
67 
 52  Hospital 
outpatient 
department 
1 wk after 
hospital 
discharge 
8 wk 
BMI51 90 67.8
–
69.5 
 35.9–35.6 37.3–44.4 Inpatient 2 d after 
hospital 
presentation 
Until 
hospital 
discharge 
Physical 
activity 
Accelerometer16 29 67.8
–
64.1 
 39.1–41.7  Inpatient 3 d after 
hospital 
presentation 
At least 3 
sessions 
Strength MVIC16,36,42,43,45,47,50,54,55,5
7 
11–196 65–
78.8 
 39.1–52 38–51.9 Inpatient, 
hospital 
outpatient 
department, 
and home 
At hospital 
presentation 
to 1 wk after 
hospital 
discharge 
7 d–8 wk 
TwQ42 60 65–
67 
 52  Hospital 
outpatient 
1 wk after 
hospital 
8 wk 
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department discharge 
MIP30 28 62.3
–
65.6 
 38  Inpatient 6–8 d after 
hospital 
presentation 
11 d 
a6MWT = 6-min walk test; AE = acute exacerbation; BMI = body mass index; CRS = computerized respiratory sounds; ESWT = endurance 755 
shuttle walk test; FEV1 = forced expiratory volume in 1 s; FEV1pp = percentage predicted FEV1; FVC = forced vital capacity; ISWT = 756 
incremental shuttle walk test; MIP = maximum inspiratory pressure; MVIC = maximal voluntary isometric contraction; NS = not stated; PEF = 757 
peak expiratory flow; SpO2 = peripheral oxygen saturation; ST = stable; TwQ = quadriceps twitch responses. 758 
759 
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Table 3. 760 
Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) Evaluation, Quality of the Measurement 761 
Property, and Cost of Patient-Reported Outcomesa 762 
Outcome Outcome 
Measure 
Study Reliability Validity Responsive
ness 
Cost 
Internal 
Consisten
cy 
Test-
Rete
st 
Criterio
n 
Validity 
Structur
al 
Validity 
Construct 
Validity 
(Hypothesis 
Testing) 
Dyspnea mBorg Kendrick et 
al, 200085 
     Poor/? Free 
VAS Lemasson et 
al, 200786 
     Poor/? Free 
mMRC Güryay et al, 
200770 
  Poor/ ?  Poor/?  Free 
MRC Steer et al, 
201271 
  Poor/ ?    Free 
eMRC Steer et al, 
201271 
  Poor/ ?    No 
information 
BDI/TDI Aaron et al, 
200272 
    Poor/? Fair/+ Not free for 
commercial 
use 
HRQL SGRQ Doll et al, 
200373 
    Fair/− Poor/? Free 
Bourbeau et 
al, 200474 
    Fair/+ Fair/− 
Menn et al, 
201087 
     Poor/? 
Katsoulas et 
al, 201066 
 Fair/+   Good/? Poor/? 
Jones et al, 
201275 
    Poor/? Poor/? 
Tu et al, 
201476 
    Poor/?  
CRQ Bourbeau et 
al, 200474 
    Fair/+ Fair/− Not free 
Tsai et al, Excellent/+   Excellent/ Poor/− Fair/− 
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200864 + 
Aaron et al, 
200272 
    Poor/? Fair/− 
CCQ Trappenburg 
et al,201077 
  Fair/?   Poor/? Not free 
Antoniu et 
al, 201467 
Poor/+ Fair/+   Fair/+ Poor/? 
Kocks et al, 
200668 
    Poor/? Poor/? 
CAT Jones et al, 
200965 
Excellent/+   Excellent/
+ 
Fair/+  Not free for 
commercial 
use Jones et al, 
201178 
    Fair/+  
Jones et al 
201275 
    Fair/+ Poor/− 
Mackay et 
al, 201288 
     Fair/+ 
Tu et al, 
201476 
    Poor/+ Fair/+ 
COPDSS Miravitlles et 
al, 201179 
  Fair/?  Poor/? Poor/? Free 
EQ-5D Menn et al, 
201087 
     Poor/? Not free for 
clinical and 
commercial 
use 
Goossens et 
al, 201189 
     Poor/? 
Miravitlles et 
al, 201179 
  Fair/?  Poor/? Fair/− 
Paterson et 
al, 200080 
    Poor/? Poor/? 
SF-6D Menn et al, 
201087 
     Poor/? Not free for 
commercial 
use 
BPQ Yohannes et 
al, 200581 
  Poor/?    Not free for 
commercial 
use 
NHP Doll et al, 
200373 
     Poor/? Not free; 
copyright 
held by 
Galen 
Research 
MYMOP Paterson et 
al, 200080 
    Poor/? Poor/? Free 
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MOS-6A Paterson et 
al, 200080 
    Poor/? Poor/? Free 
Health 
status 
EXACT-
PRO 
Leidy et al, 
201482 
    Poor/?  Not free for 
commercial 
use Leidy et al, 
201169 
Poor/+    Poor/? Poor/? 
GOLD + 
SSI 
Hutchinson 
et al, 201083 
  Poor/+    Free 
ADL MRADL Yohannes et 
al, 200581 
  Poor/?    Not free for 
commercial 
use 
LCADL Miravitlles et 
al, 201179 
  Fair/?  Poor/?  Free 
General 
symptoms 
CASA-Q Monz et al, 
201084 
    Poor/+ Poor/? No 
information 
aADL = activities of daily living; BDI/TDI = Baseline Dyspnea Index and Transition Dyspnea Index; BPQ = Breathing Problems Questionnaire; CASA-Q = Cough and Sputum 763 
Assessment Questionnaire; CAT = COPD [Chronic Obstructive Pulmonary Disease] Assessment Test; CCQ = Clinical COPD Questionnaire; COPDSS = COPD severity score; 764 
CRQ = Chronic Respiratory Disease Questionnaire; eMRC = extended Medical Research Council (MRC); EQ-5D = EuroQol 5D; EXACT-PRO = Exacerbations of Chronic 765 
Pulmonary Disease Tool–Patient-Reported Outcome; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HRQL = Health-Related Quality of Life; LCADL = London 766 
Chest Activities of Daily Living Scale; mBorg = modified Borg Scale; mMRC = modified MRC; MOS-6A = Medical Outcomes Study 6-Item General Health Survey; MRADL = 767 
Manchester Respiratory Activities of Daily Living Questionnaire; MYMOP = Measure Your Medical Outcome Profile; NHP = Nottingham Health Profile; SF-6D = Short-Form 6D; 768 
SGRQ = St George Respiratory Questionnaire; SSI = Symptom Severity Index; VAS = visual analog scale; + = positive; − = negative; ? = indeterminate. 769 
  770 
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Table 4. 771 
Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) Evaluation, Quality of the Measurement 772 
Property, and Cost of Clinical Outcomesa 773 
Outcome Outcome 
Measure 
Study Reliability Validity Responsiven
ess 
Cost 
Internal 
Consistency 
Test-
Retest 
Criterion 
Validity 
Construct 
Validity 
(Hypothesis 
Testing) 
Oxygen 
saturation 
SpO2 (%) Güryay et al, 
200770 
  Fair/+ Poor/?  Not free 
Kelly et al, 
200190 
  Fair/+ Poor/+  
Lung function PEF (pp) Emerman et 
al, 199691 
   Poor/+ Fair/+ Not free 
Güryay et al, 
200770 
   Poor/?  
FEV1 (pp 
or L) 
Güryay et al, 
200770 
  Poor/? Poor/?  Not free 
Aaron et al, 
200272 
    Poor/? 
White et al, 
200592 
   Poor/?  
FVC (pp) Güryay et al, 
200770 
   Poor/?  Not free 
CRS Morillo et al, 
201393 
  Fair/+   Not free 
Body composition BMI 
(kg/m2) 
Tsimogianni 
et al, 200994 
  Poor/+   Free 
Physical activity Time 
spent in 
weight-
bearing 
activities 
(min) 
Pitta et al, 
200695 
   Poor/+  Not free 
aBMI = body mass index; CRS = computerized respiratory sounds; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; PEF = peak expiratory flow; pp = 774 
percentage of predicted normal value; SpO2 = peripheral oxygen saturation; + = positive; − = negative; ? = indeterminate. 775 
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Records identified through database searching  
(n =82) 
Sc
re
e
n
in
g 
El
ig
ib
ili
ty
 
Id
e
n
ti
fi
ca
ti
o
n
 
Records after duplicates removed 
(n =41) 
Records screened 
(n =41) 
Records excluded based on title and/or 
abstract 
(n =18) 
Full-text articles assessed 
(n =23) 
Full-text articles excluded 
(n =15) 
Reasons for exclusion: 
• Were not original papers (n=5) 
• Outcome measures not useful for 
routine PR (n=3) 
• Not assessing measurement 
properties in patients with AECOPD 
(n=5) 
• Did not assess full outcome measure 
(n=1) 
• Language (n=1) 
In
cl
u
d
e
d
 
Studies included in review 
(n=32) 
Full-text articles included from 
references 
(n =24) 
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Figure. 
Flow diagram of the studies assessing the measurement proprieties of the outcome 
measures used in the pulmonary rehabilitation (PR) of patients with acute exacerbation of 
chronic obstructive pulmonary disease (AECOPD) (phase 2). 
